Indications
Lytenava is indicated in adults for treatment of neovascular (wet) age-related macular degeneration (nAMD).
Composition
- Active substance
- bevacizumab
Official product information
The European public assessment report holds the summary of product characteristics and the package leaflet in every EU language.
Prognia shows this product information for reference and learning. It is not treatment advice and can lag behind the official text. Always check the current product information and local protocols before prescribing.
At a glance
- Medicine
- Lytenava
- Active substance
- bevacizumab
- ATC code
- S01LA08
- Group
- Sensory organs
- Therapeutic area
- Wet Macular Degeneration
- Marketing authorisation holder
- Outlook Therapeutics NL B. V.
- Status
- Authorised
- EU authorisation
- 27 May 2024
- EMA product number